Patents Examined by Bao Q Li
  • Patent number: 10570377
    Abstract: The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: February 25, 2020
    Assignee: Replimune Limited
    Inventor: Robert Coffin
  • Patent number: 10568969
    Abstract: The present invention relates to isolated immunogenic polypeptides and their use. In one aspect, the isolated immunogenic polypeptide includes a scaffold polypeptide having a hairpin loop modified to include one or more epitopes heterologous to the scaffold polypeptide and from an amino acid loop linked by a disulfide bond. The scaffold polypeptide directs self-assembly with two other of the scaffold polypeptides to form a trimeric structure, which constrains the one or more epitopes to a conformation that is (i) substantially similar to one or more native pathogen epitopes in trimeric conformation and (ii) capable of binding an antibody reactive to the one or more native pathogen epitopes in trimeric conformation. Another aspect relates to an isolated immunogenic polypeptide that includes a scaffold polypeptide having a native loop modified to include one or more epitopes heterologous to the scaffold polypeptide and from an amino acid loop linked by a disulfide bond.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: February 25, 2020
    Assignees: New York University, Molsoft LLC, Icahn School of Medicine at Mount Sinai
    Inventors: Maxim Totrov, Xunqing Jiang, Ruimin Pan, Susan Zolla-Pazner, Xiangpeng Kong
  • Patent number: 10570191
    Abstract: This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 25, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
  • Patent number: 10548853
    Abstract: The present invention provides an oncolytic virus formulation and preparation method thereof. The oncolytic virus formulation comprises cell vesicles derived from apoptotic tumor cells and oncolytic viruses coated in the cell vesicles as an effective component. The oncolytic virus formulation uses cell vesicles derived from tumor cells themselves to coat the oncolytic viruses, so as to evade the body's immune system attack and can be targeted to the tumor treatment site, and improve the tumor-killing effect.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: February 4, 2020
    Assignee: HUBEI SOUNDNY BIOTECHNOLOGY CO., LTD.
    Inventor: Bo Huang
  • Patent number: 10548946
    Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: February 4, 2020
    Assignee: The government of the United States, as represented by the Secretary of the Army
    Inventors: Joseph Golden, Jay Hooper
  • Patent number: 10548970
    Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: February 4, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES
    Inventors: Baoming Jiang, Yuhuan Wang
  • Patent number: 10544206
    Abstract: The present invention provides a novel antibody capable of binding to a norovirus. The present invention is an antibody that consists of an amino acid sequence, wherein said amino acid sequence consists of, in an N- to C-direction, the following structural domains: N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 consists of any one of an amino acid sequences represented by SEQ ID NO: 1-SEQ ID NO: 6; the CDR2 consists of any one of an amino acid sequences represented by SEQ ID NO: 7-SEQ ID NO: 12; the CDR3 consists of any one of an amino acid sequences represented by SEQ ID NO: 13-SEQ ID NO: 17; and the antibody is capable of binding to a norovirus.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 28, 2020
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventor: Keiko Yugawa
  • Patent number: 10537630
    Abstract: Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: January 21, 2020
    Assignee: Valneva SE
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Patent number: 10538744
    Abstract: This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: January 21, 2020
    Inventor: Per Sonne Holm
  • Patent number: 10537599
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 21, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Linde Miles, John Poirier, Charles Rudin
  • Patent number: 10525127
    Abstract: The present invention Provides composition and method for stimulating immune responses against antigens without using conventional adjuvants (such as aluminum salt adjuvants, oil-in-water emulsion adjuvants, toll-like receptor agonist adjuvants, and the like). The composition contains p14.7 protein and an antigen to which the stimulated illumine responses are desired. The p14.7 protein functions as an adjuvant so that the immune responses to the antigen stimulated by the composition comprising p14.7 protein and the antigen are greater than the immune responses stimulated by the antigen alone. The current invention also provides a method for producing thermostable vaccines and a simple strategy for avoiding vaccine cold-chain maintenance by lyophilization.
    Type: Grant
    Filed: March 31, 2018
    Date of Patent: January 7, 2020
    Assignee: Femtomab
    Inventor: Wenyun Zhou
  • Patent number: 10519220
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: December 31, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Kannan Tharakaraman
  • Patent number: 10517942
    Abstract: Creation of HIV-1 vaccine immunogens based on glycopeptide scaffolds containing sequences from the V1/V2/V3 and C3 domains of HIV-1 gp120 that is able to bind multiple broadly neutralizing antibodies when expressed in mammalian cells that incorporate mannose-5 and mannose-9 glycans.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 31, 2019
    Assignee: The Regents of the University of California
    Inventors: Phillip Berman, Rachel Doran, Gabriel Byrne, Rebecca Dubois, Javier Morales, Bin Yu, Gerardo Perez, Kathryn Mesa, David Alexander
  • Patent number: 10512682
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: December 24, 2019
    Assignee: Takeda Vaccines, Inc.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 10512698
    Abstract: This invention presents the method and use of the AAV-XBP1s/GFP virus, in the prevention and treatment of amyotrophic lateral sclerosis, as presented in the in vivo studies in FIG. 6.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: December 24, 2019
    Assignee: UNIVERSIDAD DE CHILE
    Inventors: Claudio Andrés Hetz Flores, Vicente Spiro Valenzuela Paterakis
  • Patent number: 10501529
    Abstract: Provided herein are a mutant envelope protein of Zika virus and a nucleic acid molecule including a nucleotide sequence encoding the mutant envelope protein. The mutant envelope protein, which preferably has a threonine substitution at 105th position, or an asparagine substitution at 248th position and a threonine substitution at 250th position in an amino acid sequence of SEQ ID NO: 1, includes an N-glycan masking a fusion loop region of the mutant envelope protein of Zika virus. Also provided herein is a vaccine composition, including the mutant envelope protein or a recombinant virus including the nucleic acid molecule. Also provided herein is a method of preventing Zika virus infection and reducing antibody-dependent enhancement of dengue virus infection, including administering to a subject in need thereof an effective amount of a vaccine composition including the mutant envelope protein of Zika virus.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 10, 2019
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Suh-Chin Wu, Shao-Ping Yang, Hsiao-Han Lin
  • Patent number: 10478638
    Abstract: The present invention relates to a recombinant self-assembled protein comprising a target-oriented peptide and a use thereof The recombinant self-assembled protein according to the present invention, comprising a target-oriented peptide, does not require an additional process for providing target-orientedness, and is thus capable of delivering a desired drug to a target tissue or target cell without using additives, such as chemical binders or stabilizers; therefore, the protein can be used for photothermal therapy, drug delivery, imaging, or the like. In particular, according to the present invention, it is possible to prepare gold-protein nanoparticle fusions in which uniform high-density gold nanoparticles having target-orientedness are bound to protein surfaces, without an additional process of surface stabilization or process for providing target-orientedness.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: November 19, 2019
    Assignee: Korea University Research and Business Foundation
    Inventors: Jeewon Lee, Koo-Chul Kwon
  • Patent number: 10478486
    Abstract: The present invention relates to a vaccine composition comprising an effective amount of a replication-competent controlled recombinant virus. Further encompassed are uses in immunization and methods of immunization employing compositions comprising a replication-competent controlled recombinant virus of the invention.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: November 19, 2019
    Assignee: HSF PHARMACEUTICALS SA
    Inventor: Richard W Voellmy
  • Patent number: 10471137
    Abstract: Compositions, vaccines and methods for inducing protective immunity against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of HIV.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 12, 2019
    Assignees: Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan Barouch, Johanna Schuitemaker, Maria Grazia Pau, Danielle Van Manen, Frank Tomaka, Jennifer Anne Hendriks
  • Patent number: 10464986
    Abstract: The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: November 5, 2019
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno